AU
UK
CA
NZ
IND
US
Not every merger announcement is created equal. Some are defensive moves by companies running low onOptions. Others are genuine resets, moments where two organisations come together and the result is more interesting than either was on its own. The deal announced between Rallybio Corporation …
Why LIXTE Biotechnology Holdings (NASDAQ: LIXT) Stock Jumped Today
There are moments in biotech when the market's verdict arrives swiftly and without ambiguity. Tuesday was one such moment for Edgewise Therapeutics, a Boulder-based clinical-stage company quietly building a case for itself in the fiercely competitive muscular dystrophy space. An 18% single-session gain is …
There is a particular kind of disappointment in biotech that is harder to absorb than a failed clinical trial. A trial failure, however painful, belongs to science. What happened to Fulcrum Therapeutics is different. Pociredir worked. The fetal hemoglobin numbers moved. There were no …
When a biotech company's board formally lists an "orderly wind-down" as one of its strategic options, the market tends to take that language atFace Value. On Tuesday, investors in Jasper Therapeutics (Nasdaq: JSPR) did exactly that, sending shares down 36% to $0.53 in a …
A Regulatory Catalyst With Market Sizing Context
What ResMed Just Did and Why It Matters
Key HighlightsREPL exploded 85.68% on 29 May 2026 to $8.69 (pre-market +60% before the open) after FDA alignment on a path forward for resubmission of the BLA for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma, with the FDA indicating priority review upon receipt.TradingVolumeof …
Key HighlightsCCCC surged 19.40% on 29 May 2026 to $4.37 after Q1 2026Revenuebeat of $6.2M versus $4.42M consensus (+40%), coupled with progress in the cemsidomide multiple myeloma program and a strategicPartnershipwith Roche.Roche collaboration brought a $20M upfront payment for degrader-antibody conjugate programs, validating C4's …
Please wait processing your request...